Ampio Pharmaceuticals' Ampion, used to treat knee osteoarthritis, exceeded Phase 3 clinical trial standards set by the Osteoarthritis Research Society International.
Here are five highlights:
1. Seventy-one percent of Ampion-treated patients met the OMERACT-OARSI responder criteria, beating the 30 percent threshold to be classified a meaningful treatment for severe knee osteoarthritis.
2. Ampion-treated patients experienced a 53 percent decrease in pain and a 50 percent improvement in function. Additionally, patients reported a 45 percent improvement in quality of life.
3. Ampion is the first intra-articular injection to treat knee osteoarthritis.
4. Ampion has been administered to more than 900 patients throughout each phase of the clinical trial. No patients reported drug related treatment-emergent adverse events.
5. The company plans to distribute more details about the phase 3 clinical trial at an upcoming scientific meeting. The company will submit results for publication as well.